BMJ:冠状动脉旁路移植术后抗血栓治疗

2019-10-11 MedSci MedSci原创

研究认为,在阿司匹林中加入替格瑞洛或氯吡格雷对预防冠状动脉旁路移植术后隐静脉移植失败有益

近日研究人员评估了口服抗血栓药物预防冠状动脉旁路移植术后隐静脉移植失败的效果。

本次研究为系统综述及荟萃分析研究,收集截至2019年1月的相关资料,接受口服抗血栓药物(抗血小板或抗凝剂),预防冠状动脉旁路移植术后隐静脉移植失败的参与者(年龄≥18岁)。研究的主要疗效终点为隐静脉移植失败,主要安全终点为大出血。继发终点为心肌梗死和死亡。

21篇文章,涉及20项随机对照试验,包含3266条引文,总计4803名参与者,分析了9项不同的干预措施(8个活性药物和1个安慰剂)。与阿司匹林单药相比,中等程度证据支持使用阿司匹林+替格瑞洛 (OR:0.50,治疗次数10)或阿司匹林+氯吡格雷(0.60,19)的双重抗血小板治疗以减少隐静脉移植失败风险。不同的抗血栓治疗方法在大出血、心肌梗死和死亡方面有明显的差异。

研究认为,在阿司匹林中加入替格瑞洛或氯吡格雷对预防冠状动脉旁路移植术后隐静脉移植失败有益。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2019-11-20 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2020-06-20 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1848868, encodeId=666218488689a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Nov 20 02:18:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998988, encodeId=0ee4199898842, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 20 07:18:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018987, encodeId=ed22201898e90, content=<a href='/topic/show?id=b2f35881810' target=_blank style='color:#2F92EE;'>#旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58818, encryptionId=b2f35881810, topicName=旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Sep 07 16:18:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355501, encodeId=4a1c135550178, content=<a href='/topic/show?id=f0ff308e898' target=_blank style='color:#2F92EE;'>#冠状动脉旁路移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30878, encryptionId=f0ff308e898, topicName=冠状动脉旁路移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385525, encodeId=a5cc1385525e8, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574128, encodeId=708f15e4128a6, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Oct 13 09:18:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2019-10-13 gwc388

相关资讯

Eur Heart J:左侧感染性心内膜炎赘生物尺寸和手术治疗与6个月死亡率的关联

在这项观察性研究中,赘生物尺寸>10mm的左侧IE与6个月死亡率升高相关,但依赖于治疗策略。

Lancet Neurol:抗血栓治疗可降低脑海绵状畸形患者出血及神经缺损风险

研究发现,抗血栓治疗可降低脑海绵状畸形引起颅内出血或局灶性神经功能缺损风险

Eur J Clin Pharmacol:哪些因素影响房颤患者预防卒中的抗血栓治疗决策?

2017年6月,发表在《Eur J Clin Pharmacol》的一项由瑞典和荷兰科学家进行的研究考察了斯德哥尔摩地区引入NOACs后,房颤(AF)患者预防卒中的抗血栓治疗决策相关因素。

JACC:房颤患者经导管主动脉瓣置换术后的抗血栓治疗和心血管结局

在接受TAVR治疗的既往房颤患者中,伴或不伴抗凝治疗的抗血小板治疗与2年的卒中风险降低相关。

Eur Heart J:AF患者PCI后抗血栓治疗,双重还是三重?

2018年5月,发表在《Eur Heart J》的一项随机临床试验的系统评价和Meta分析调查了双重vs三重抗血栓治疗在进行了经皮冠状动脉介入(PCI)治疗的房颤(AF)患者中的安全性和有效性

BMJ:新型抗血栓药DOAC可有效替代华法林,安全性更高!

用于治疗严重血栓的新药物与老的抗凝药物华法林相比,不存在较大的出血风险,该研究报告今天发表在“BMJ”上。